


Screening Phase
Up to 28 Days
Transition Phase
1 to 4 Months
1 to 5 Injections
Maintenance Phase
1 or 3 Months
1 Injection
Randomize
Double-blind Phased
12 Months
4 Injections
Low-dose exclusion groups: not eligible, PP1M 50 or 75 mg eq.
Not previously stabilized with moderate or higher dose of PP1M or PP3M
Previously stabilized with moderate or higher dose of PP1M or PP3M
PP1M, 50 to 150 mg eq.
Moderate-dose baseline groups: PP1M 100 mg eq., or PP3M 350 mg eq.
Higher-dose baseline groups: PP1M 150 mg eq., or PP3M 525 mg eq.
PP3M 350 mg eq. (active control)
PP6M 700 mg eq. (investigational drug) with alternating placebo
PP3M 525 mg eq. (active control)
PP6M 1000 mg eq. (investigational drug) with alternating placebo

FIG. 1



Number of Subjects Remaining

PP3M	*224*	*223*	*221*	*219*	*215*	*211*	*205*	*200*	*196*	*193*	*193*	*193*	*193*	*160*	*1*	*0*	*0*
PP6M	**478**	**471**	**465**	**457**	**447**	**440**	**436**	**417**	**408**	**404**	**403**	**399**	**393**	**328**	**1**	**1**	**0**

Cumulative Number of Subjects with Relapse

PP3M	*0*	*0*	*0*	*1*	*2*	*3*	*6*	*8*	*8*	*10*	*10*	*10*	*10*	*11*	*11*	*11*	*11*
PP6M	**0**	**3**	**8**	**11**	**13**	**18**	**20**	**25**	**27**	**29**	**29**	**29**	**32**	**35**	**36**	**36**	**36**

FIG. 2



Difference (%) and 95% CI in Relapse-Free Rate
Diff % (95% CI)
N (PP3M)
N (PP6M)
Primary: DB Phase ITT
-2.9 (-6.8, 1.1)
224
478
DB Phase Per Protocol
-3.2 (-7.1, 0.7)
217
462
-15
-10
-5
0
5
Favors PP3M
Favors PP6M

FIG. 3



Double blind phase 350 mg eq. PP3M (n=104)
Double blind phase 525 mg eq. PP3M (n=114)
Double blind phase 700 mg eq. PP6M (n=226)
Double blind phase 1000 mg eq. PP6M (n=244)
Plasma conc. of paliperidone (ng/mL)
0
10
20
30
40
50
60
70
80
1
29
57
85
113
141
169
197
225
253
281
309
337
365
Day

FIG. 4



Oral
Median time to relapse
58 Days
PP1M
Median time to relapse
172 Days
PP3M
Median time to relapse
395 Days
PP6M
Median time to relapse
Not detemined
Paliperidone Concentration (ng/mL)
75
50
25
7.5
0
0
6
12
18
24
30
36
Time since last SS injection (months)

FIG. 5



High Dose
Concentration, ng/mL
300
100
10
1
0.1
Scheduled
7 months after last dose
7.5 months after last dose
0
6
12
18
24
30
36
42
48
54
Time since first PP6M, months
PP1M initiation
PP1M maintenance
Regular PP6M
Delay
PP1M reinitiation
1 PP1M dose

FIG. 6



High Dose
Concentration, ng/mL
300
100
10
1
0.1
Scheduled
8 months after last dose
10 months after last dose
11 months after last dose
0
6
12
18
24
30
36
42
48
54
Time since first PP6M, months
PP1M initiation
PP1M maintenance
Regular PP6M
Delay
PP1M reinitiation
2 PP1M dose

FIG. 7



High Dose
Concentration, ng/mL
300
100
10
1
0.1
Scheduled
12 months after last dose
15 months after last dose
18 months after last dose
0
6
12
18
24
30
36
42
48
54
60
Time since first PP6M, months
PP1M initiation
PP1M maintenance
Regular PP6M
Delay

FIG. 8



Weight: Mean Change and Abnormal Change from DB Baseline
Weight Gain (kg)
2
1.5
1
0.5
0
0.96
PP3M
0.1
PP6M
Weight (kg)
Mean Change from Double Blind Baseline to 12-month Endpoint (DB) in Weight (kg)
PP3M (N=219) 0.96 (5.103)
PP6M (N=473) 0.10 (4.959)
Percent Subjects
14
12
10
8
6
4
2
0
PP3M
PP6M
PP3M
PP6M
Decrease ≥ 7%
Increase ≥ 7%
Weight percent change
PP3M (N=224)
PP6M (N=478)
Number of Subjects With Abnormal Weight Percent Change From Baseline (DB) at End Point (DB)
PP3M (N=224)
PP6M (N=478)
Decrease ≥ 7% 15 (6.8%) 43 (9.1%)
Increase ≥ 7% 29 (13.2%) 50 (10.6%)

FIG. 9



Double Blind Dose
PP3M (N=224)
PP6M (N=478)
2
1.5
1
0.5
0
-0.5
-1
Mean Change Body Weight
1.42
0.28
1.15
-0,53
0.3
0.71
NORMAL <25
OVERWEIGHT 25-<30
OBESE >=30
Classification of Body Weight (BMI)

FIG. 10



Dose Regimen DB
PP3M (N=224)
PP6M (N=478)
Mean Change Body Weight
6.00
5.00
4.00
3.00
2.00
1.00
0.00
-1.00
-2.00
Age Group
18-25
26-50
51-65
>65

FIG. 11